Eos Management L.P. bought a new stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 4,283 shares of the medical research company’s stock, valued at approximately $965,000.
Other large investors also recently bought and sold shares of the company. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA in the 4th quarter valued at $25,000. International Assets Investment Management LLC purchased a new position in shares of IQVIA in the 4th quarter worth $27,000. Gilpin Wealth Management LLC purchased a new position in shares of IQVIA in the 4th quarter worth $27,000. CrossGen Wealth LLC acquired a new position in IQVIA in the fourth quarter valued at $28,000. Finally, Measured Wealth Private Client Group LLC purchased a new stake in IQVIA during the third quarter valued at about $30,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.
Analyst Ratings Changes
IQV has been the topic of a number of research reports. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the stock from $174.00 to $213.00 in a report on Monday, March 9th. Royal Bank Of Canada initiated coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price for the company. HSBC set a $210.00 target price on shares of IQVIA in a research report on Wednesday, June 3rd. Evercore restated an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $222.56.
IQVIA Trading Up 0.2%
NYSE:IQV opened at $168.14 on Friday. The business’s 50-day moving average is $173.63 and its two-hundred day moving average is $191.68. The firm has a market capitalization of $28.06 billion, a PE ratio of 20.84, a price-to-earnings-growth ratio of 1.44 and a beta of 1.21. IQVIA Holdings Inc. has a 12 month low of $153.01 and a 12 month high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.
IQVIA (NYSE:IQV – Get Free Report) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the prior year, the business earned $2.70 earnings per share. The company’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.
IQVIA announced that its Board of Directors has initiated a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.
IQVIA Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Further Reading
- Five stocks we like better than IQVIA
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
